TRAN, THUY-ANH,DO, QUYEN-QUYEN,ULLMAN, BRETT,NAGURA, MAIKO,BLACKBURN, ANTHONY C.
申请号：
CA3026024
公开号：
CA3026024A1
申请日:
2017.06.05
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
The present invention relates to compounds of Formula (Ia) and pharmaceuticalcompositions thereof that modulate theactivity of the beta-3 adrenergic receptor. Compounds of the present inventionand pharmaceutical compositions thereof are directed tomethods useful in the treatment of a beta-3 adrenergic receptor-mediateddisorder, such as, heart failure； cardiac performance in heartfailure； mortality, reinfarction, and/or hospitalization in connection withheart failure； acute heart failure； acute decompensated heartfailure； congestive heart failure； severe congestive heart failure； organdamage associated with heart failure (e.g., kidney damage orfailure, heart valve problems, heart rhythm problems, and/or liver damage)；heart failure due to left ventricular dysfunction； heart failurewith normal ejection fraction； cardiovascular mortality following myocardialinfarction； cardiovascular mortality in patients with leftventricular failure or left ventricular dysfunction； left ventricular failure；left ventricular dysfunction； class II heart failure using theNew York Heart Association (NYHA) classification system； class III heartfailure using the New York Heart Association (NYHA)classification system； class IV heart failure using the New York HeartAssociation (NYHA) classification system； LVEF <； 40% byradionuclide ventriculography； LVEF <；=35% by echocardiography orventricular contrast angiography； and conditions related thereto.
